Global Stem Cell Therapy Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

November 2017 | 213 pages | ID: GE958218055EN
Precision Business Insights (PBI)

Abstracts

Global Stem Cell Therapy Market:

Global stem cell therapy market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for stem cell therapy is projected to reach US$ XX Mn by 2023.

Stem cell therapy involves use of stem cells to treat various diseases or disorders. Stem cells are fundamental for every tissue and organ in the body. Stem cells are indistinguishable biological cells that are able to differentiate into specialised cells (liver cells, cardiac cells etc.) and can renew itself (through mitosis) to produce more stem cells. Stem cells have the ability to replicate, repair, and replace other damaged tissues in the human body. In addition, stem cell based therapies are also used to treat several chronic diseases such as blood disorders, cancer and others.

Growing awareness about the potency of stem cells in disease management, development of advanced gene based analysis techniques and increase in public, private investments in stem cell research are acting as growth drivers for stem cell therapy market. In addition, identification of new stem cell lines and development of infrastructure for stem cell banking & processing are propelling the growth of the global stem cell therapy market. However, ethical issues involved in stem cells research such as destruction of human embryos, religious beliefs are considered as road blocks for adaptation of stem cell therapy by patients. However, stringent regulations to conduct trials on humans, high-cost of research and storage of stem cells are some restraining factors for stem cell therapy market.

Stem cell therapy market has been segmented on the basis of treatment mode, cell types, application, technology, and end-user

Based on treatment, stem cell therapy market is segmented into

• Allogeneic
• Autologous

Based on cell type, stem cell therapy market is segmented into

• Adult Stem cells
• Induced Pluripotent Stem cells
• Human Embryonic Stem Cells
• Others

Based on technology, stem cell therapy market is segmented into

• Cell Production
• Cell Acquisition
• Cryopreservation

Based on end-user, stem cell therapy market segmented into

• Hospitals
• Ambulatory Centers
• Research Centers

Stakeholders in stem cell therapy such as academic institutions and research firms are collaborating in development of stem cell therapy and industry collaborations also projecting enormous growth of stem cell therapy market. For instance, in November 2015, Cellular Dynamics International, Inc. (FUJIFILM) collaborated with Roche to supply iCell (CDI's induced pluripotent stem cell derived) products that enables in identification of novel drug candidates at the early stages of drug discovery. Similarly, in May 2017, Magenta Therapeutics, entered into strategic partnership with Be The Match BioTherapies, to improve and expand the use of curative stem cell transplantation.

Geographically stem cell therapy market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Among the regions, North America dominates global stem cell therapy market due to factors such as increasing prevalence of chronic diseases, growing awareness, and rising investment in research and development activities. In Asia Pacific region, due to the favourable government policies, development healthcare infrastructure, industry collaborations in research and developments expected to boost stem cell therapy market. For instance, in April 2017, Plasticell, a developer of stem cell technologies and cell-based therapies, has announced that it has signed agreements with the Agency for Science, Technology and Research (ASTAR), Singapore, and the Nanyang Technological University (NTU), Singapore, to progress its therapeutic stem cell pipeline.

Some of the players in stem cell therapy market are Cytori Therapeutics Inc. (U.S.), Fibrocell Science (U.S.), Cellartis AB (Cellectis) (France), BioTime, Inc. (U.S.), GE Healthcare (U.S.), Thermo Fisher Scientific (U.S.), STEMCELL Technologies Inc. (Canada), Fujifilm Holdings Corporation (Japan), Vericel Corporation (Aastrom Bioscience) (U.S.), Brainstorm cell therapeutics (U.S.), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), Celgene Corporation (U.S.), and Osiris Therapeutics, Inc. (U.S.) to name a few.

In February 2016, Mesoblast Limited’s licensee in Japan, JCR Pharmaceuticals Co. Ltd., launched “TEMCELL HS Inj”, the first allogeneic cell therapy to be fully approved in Japan, for the treatment of acute graft versus host disease in children and adults

REPORT OUTLINE:

• The report provides granular level information about the market size, regional market share and forecast from 2017-2023
• The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
• The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry
• The report tracks recent innovations, key developments and startup’s details that are working in the industry
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL STEM CELL THERAPY MARKET INTRODUCTION

2.1. Global Stem Cell Therapy Market– Taxonomy
2.2. Global Stem Cell Therapy Market–Definitions
  2.2.1. Treatment Type
  2.2.2. Cell Type

3. GLOBAL STEM CELL THERAPY MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Stem Cell Therapy Market Dynamics – Factors Impact Analysis
3.6. Global Stem Cell Therapy Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan

4. GLOBAL STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL STEM CELL THERAPY MARKET, BY TREATMENT TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Allogeneic
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Autologous
  5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.2.3. Market Opportunity Analysis

6. GLOBAL STEM CELL THERAPY MARKET FORECAST, BY CELL TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Adult Stem Cells
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.1.3. Market Opportunity Analysis
6.2. Induced Pluripotent Stem Cells
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.2.3. Market Opportunity Analysis
6.3. Human Embryonic Stem Cells
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.3.3. Market Opportunity Analysis
6.4. Others
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  6.4.3. Market Opportunity Analysis

7. GLOBAL STEM CELL THERAPY MARKET FORECAST, BY END USER, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospitals
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.1.3. Market Opportunity Analysis
7.2. Ambulatory Surgical Centers
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.2.3. Market Opportunity Analysis
7.3. Research Centers
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  7.3.3. Market Opportunity Analysis

8. GLOBAL STEM CELL THERAPY MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
  8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.1.3. Market Opportunity Analysis
8.2. Europe
  8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
  8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.3.3. Market Opportunity Analysis
8.4. Latin America
  8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
  8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  8.5.3. Market Opportunity Analysis
8.6. Global Stem Cell Therapy Market- Opportunity Analysis Index - By Treatment Type, By Cell Type, By End User, and Region, 2017 – 2023

9. NORTH AMERICA STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  9.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    9.1.1.1. Allogeneic
    9.1.1.2. Autologous
  9.1.2. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.2.1. Adult Stem Cells
    9.1.2.2. Induced Pluripotent Stem Cells
    9.1.2.3. Human Embryonic Stem Cells
    9.1.2.4. Others
  9.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.3.1. Cell Production
    9.1.3.2. Cell Acquisition
    9.1.3.3. Cryopreservation
  9.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    9.1.4.1. Hospitals
    9.1.4.2. Ambulatory Surgical Centers
    9.1.4.3. Research Centers
  9.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
    9.1.5.1. U.S.
    9.1.5.2. Canada
  9.1.6. North America Stem Cell Therapy Market- Opportunity Analysis Index - By Treatment Type, By Cell Type, By Technology, By End User, and Country, 2017 – 2023
  9.1.7. North America Stem Cell Therapy Market Dynamics – Trends

10. EUROPE STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  10.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    10.1.1.1. Allogeneic
    10.1.1.2. Autologous
  10.1.2. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.2.1. Adult Stem Cells
    10.1.2.2. Induced Pluripotent Stem Cells
    10.1.2.3. Human Embryonic Stem Cells
    10.1.2.4. Others
  10.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.3.1. Cell Production
    10.1.3.2. Cell Acquisition
    10.1.3.3. Cryopreservation
  10.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.4.1. Hospitals
    10.1.4.2. Ambulatory Surgical Centers
    10.1.4.3. Research Centers
  10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    10.1.5.1. Germany
    10.1.5.2. UK
    10.1.5.3. France
    10.1.5.4. Spain
    10.1.5.5. Italy
    10.1.5.6. Russia
    10.1.5.7. Poland
    10.1.5.8. Rest of Europe
  10.1.6. Europe Stem Cell Therapy Market- Opportunity Analysis Index - By Treatement Type, By Cell Type Type, By Technology, By End User, and Country, 2017 – 2023
  10.1.7. Europe Stem Cell Therapy Market Dynamics – Trends

11. ASIA-PACIFIC STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  11.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    11.1.1.1. Allogeneic
    11.1.1.2. Autologous
  11.1.2. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.2.1. Adult Stem Cells
    11.1.2.2. Induced Pluripotent Stem Cells
    11.1.2.3. Human Embryonic Stem Cells
    11.1.2.4. Others
  11.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.3.1. Cell Production
    11.1.3.2. Cell Acquisition
    11.1.3.3. Cryopreservation
  11.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    11.1.4.1. Hospitals
    11.1.4.2. Ambulatory Surgical Centers
    11.1.4.3. Research Centers
  11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
    11.1.5.1. Japan
    11.1.5.2. China
    11.1.5.3. India
    11.1.5.4. ASEAN
    11.1.5.5. Australia & New Zealand
    11.1.5.6. Rest of Asia-Pacific
  11.1.6. Asia-Pacific Stem Cell Therapy Market- Opportunity Analysis Index - By Treatement Type, By Cell Type Type, By Technology, By End User, and Country, 2017 – 2023
  11.1.7. Asia-Pacific Stem Cell Therapy Market Dynamics – Trends

12. LATIN AMERICA STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  12.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    12.1.1.1. Allogeneic
    12.1.1.2. Autologous
  12.1.2. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.2.1. Adult Stem Cells
    12.1.2.2. Induced Pluripotent Stem Cells
    12.1.2.3. Human Embryonic Stem Cells
    12.1.2.4. Others
  12.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.3.1. Cell Production
    12.1.3.2. Cell Acquisition
    12.1.3.3. Cryopreservation
  12.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.4.1. Hospitals
    12.1.4.2. Ambulatory Surgical Centers
    12.1.4.3. Research Centers
  12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    12.1.5.1. Brazil
    12.1.5.2. Mexico
    12.1.5.3. Argentina
    12.1.5.4. Venezuela
    12.1.5.5. Rest of Latin America
  12.1.6. Latin America Stem Cell Therapy Market- Opportunity Analysis Index - By Treatement Type, By Cell Type Type, By Technology, By End User, and Country, 2017 – 2023
  12.1.7. Latin America Stem Cell Therapy Market Dynamics – Trends

13. MIDDLE EAST & AFRICA STEM CELL THERAPY MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

  13.1.1. Treatment Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.1.1. Allogeneic
    13.1.1.2. Autologous
  13.1.2. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.2.1. Adult Stem Cells
    13.1.2.2. Induced Pluripotent Stem Cells
    13.1.2.3. Human Embryonic Stem Cells
    13.1.2.4. Others
  13.1.3. Technology Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.3.1. Cell Production
    13.1.3.2. Cell Acquisition
    13.1.3.3. Cryopreservation
  13.1.4. End User Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
    13.1.4.1. Hospitals
    13.1.4.2. Ambulatory Surgical Centers
    13.1.4.3. Research Centers
  13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
    13.1.5.1. Gulf Cooperation Council (GCC) Countries
    13.1.5.2. Israel
    13.1.5.3. South Africa
    13.1.5.4. Rest of MEA
  13.1.6. MEA Stem Cell Therapy Market- Opportunity Analysis Index - By Treatment Type, By Cell Type, By Technology, By End User, and Country, 2017 – 2023
  13.1.7. MEA Stem Cell Therapy Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  14.2.1. Cytori Therapeutics Inc. (U.S.)
  14.2.2. Fibrocell Science (U.S.)
  14.2.3. Cellartis AB (Cellectis) (France)
  14.2.4. BioTime, Inc. (U.S.)
  14.2.5. GE Healthcare (U.S.)
  14.2.6. Thermo Fisher Scientific (U.S.)
  14.2.7. STEMCELL Technologies Inc. (Canada)
  14.2.8. Fujifilm Holdings Corporation (Japan)
  14.2.9. Vericel Corporation (Aastrom Bioscience) (U.S.)
  14.2.10. Brainstorm cell therapeutics (U.S.)
  14.2.11. Osiris Therapeutics, Inc. (U.S.)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS